7- hydroxy- 5,11- dioxotetranorprostane- 1,16- dioic acid

01/01/2015 - "Further studies are warranted to assess potential utility of urinary PGE-M in assessing cancer prevention efficacy."
02/01/2012 - "Our study suggests that PGE-M may be a useful risk marker for assessing the risk of harboring clinically more important versus less important colorectal neoplasia."
08/15/2005 - "Levels of urinary PGE-M were quantified in a blinded fashion using mass spectrometry and compared with smoking history and tumor status. "
12/01/2014 - "Among these women, risk of breast cancer increased from 1.00 (reference) to 1.06 (95% CI, 0.56-1.99), 1.50 (95% CI, 0.79-2.83), and 2.32 (95% CI, 1.24-4.41) for the lowest to highest quartiles of PGE-M, and such associations were stronger among those who were diagnosed with cancer within the first four years of sample collection. "
01/01/2023 - "Urinary PGE-M level may be used as a non-invasive indicator for estimating cancer risk."

01/01/2023 - "We conclude urinary PGE-M is associated with the risk of developing high-risk adenomas. "
01/01/2023 - "When compared to people with the lowest urine PGE-M levels (first quartile), people with greater urinary PGE-M levels had a higher chance of developing high-risk colorectal adenomas, with an adjusted odds ratio (95% CI) of 1.65 (0.76-3.57) in the fourth quartile group, (p= 0.013). "
01/01/2023 - "There was no significant change in PGE-M levels, between the control group and the low-risk adenoma group. "
01/01/2023 - "We conducted research to evaluate the association between urinary levels of the PGE-M and the risk of colorectal adenomas. "
01/01/2016 - "PGE-M seems to be the most interesting and promising urinary marker for CRC and adenoma risk assessment and for CRC screening. "

11/01/2009 - "Importantly, patients with high baseline levels of urinary PGE-M had a significantly greater risk of disease progression (hazard ratio, 4.76, 95% CI, 1.31-17.30; P < 0.01) and death (hazard ratio, 9.54; 95% CI, 1.17-77.7; P = 0.01) than patients with low baseline levels of urinary PGE-M. "
06/01/2013 - "In agreement with previous reports, their findings indicate that urinary PGE-M may serve as a promising biomarker for prognosticating cancer risk and disease progression."
11/01/2009 - "Median urinary PGE-M levels were significantly higher in HNSCC patients with disease progression (21.7 ng/mg creatinine) compared with patients without (13.35 ng/mg creatinine; P = 0.03). "

11/15/2004 - "Levels of PGE-M were found to be greatly increased in humans with unresectable non-small cell cancer of the lung, and this increase is dramatically reduced by administration of the COX-2 inhibitor celecoxib, implying that COX-2 contributes significantly to the overproduction of PGE2. "

12/18/1975 - "In patients with hypercalcemia and solid tumors the excretion of the major urinary metabolite of the E prostaglandins, 7 alpha-hydroxy-5, 11-diketotetranorprostane-1, 16-dioic acid (PGE-M), was significantly greater than normal, P LESS THAN 0.01 (median of 58.4 and 7.1 ng per milligram of creatinine respectively). "